Text-only version of this email
Windtree Therapeutics, Inc
October 30, 2024 8:00 AM EDTWindtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for
Planned Completion of Phase 2b and Transition to Phase 3
View this release →
Or click here to view all releases.
Show all